MEDULLARY THYROID CANCER
Clinical trials for MEDULLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new MEDULLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for MEDULLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted pill shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with a specific RET gene change. The main goal is to see if the drug can shrink tumors. Participants take the drug daily and are monitored for side …
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
New pill shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tests an oral drug called LOXO 292 in children and teens with advanced solid or brain tumors that have a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors or stop them from growing. About 36 participants will receive the drug, a…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
Could a lower dose of this cancer drug be just as effective?
Disease control OngoingThis study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as a higher dose (140 mg) in people with advanced medullary thyroid cancer that has spread. The goal is to see if the lower dose can control the cancer just as long while causing fewer side effec…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE4 • Sponsor: Exelixis • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Targeted pill shrinks tumors in people with RET-driven cancers
Disease control OngoingThis study tested an oral drug called selpercatinib in 857 people with advanced solid tumors that have a specific RET gene change. The goal was to see if the drug is safe and can shrink tumors. While it may control the cancer, it is not a cure, and ongoing treatment is needed.
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug shows promise in slowing rare thyroid cancer
Disease control OngoingThis study tests whether a new drug called selpercatinib works better than standard treatments for people with a rare type of thyroid cancer (medullary thyroid cancer) that has a specific gene change (RET mutation) and has spread or cannot be removed by surgery. About 291 adults …
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 08, 2026 12:03 UTC